Singapore manufacturing defies odds in January
While manufacturing data was a pleasant upside surprise, we would caution against any exuberance as the spread of the coronavirus could dent activity in February and the months to come
| 3.4% |
January manufacturing growthyear-on-year |
| Higher than expected | |
A surprising manufacturing bounce
Singapore’s January manufacturing data caught the consensus, which was centred on a 5.8% year-on-year fall, on the wrong footing. Instead, output surged by 3.4%, defying the unfavourable base year effect as well as continued weak non-oil domestic exports in January. The outbreak of Covid-19 was another factor behind the expectations for a weaker reading.
A seasonally-adjusted 18.2% monthly bounce, on top of a 6.3% rise in December (revised up from 4.1% initial estimate) also contrasts with the expectation of a decline. This could be surmised as either front-loading ahead of the Lunar New Year holiday or a positive response to the phase one trade deal between China and the US. On the flip-side, it probably did not capture the impact of an extended post-holiday slump due to the Covid-19 outbreak.
59% surge in pharma explains it all
Unsurprisingly though, just as the coronavirus emerged as a serious health emergency, the pharmaceutical sector kicked into high gear. Indeed, it was the main source of overall manufacturing strength with a 59% year-on-year (78% month-on-month unadjusted) leap in output. Growth in all the other main manufacturing sectors, except precision engineering, remained in negative territory.
An 18% surge in engineering may reflect the delivery of ongoing projects, while the sector has yet to succumb to the broader slack elsewhere. And, electronics was a mixed bag in January with continued weak exports, yet a bit firmer output.
But it failed to cheer markets
While this was a pleasant upside surprise, it failed to cheer the markets - the Strait Times Index of stock prices remained in the red and the Singapore dollar was little moved. Investors are likely pricing in more disappointing data ahead.
The risk of this entire bounce being reversed in February can’t be ignored in light of prolonged slack due to the spread of the virus this month. The combined January-February growth will remove the Lunar New Year impact and also act as an initial gauge of the impact of the disease that’s now spreading beyond Asia.
We continue to see a likelihood of the economy sliding into a recession in the first half of the year, before accelerated fiscal policy support, and possibly an easing by the Monetary Authority of Singapore in April helps the recovery over the rest of the year.
Download
Download article
27 February 2020
Good MornING Asia - 27 February 2020 This bundle contains 3 articles"THINK Outside" is a collection of specially commissioned content from third-party sources, such as economic think-tanks and academic institutions, that ING deems reliable and from non-research departments within ING. ING Bank N.V. ("ING") uses these sources to expand the range of opinions you can find on the THINK website. Some of these sources are not the property of or managed by ING, and therefore ING cannot always guarantee the correctness, completeness, actuality and quality of such sources, nor the availability at any given time of the data and information provided, and ING cannot accept any liability in this respect, insofar as this is permissible pursuant to the applicable laws and regulations.
This publication does not necessarily reflect the ING house view. This publication has been prepared solely for information purposes without regard to any particular user's investment objectives, financial situation, or means. The information in the publication is not an investment recommendation and it is not investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Reasonable care has been taken to ensure that this publication is not untrue or misleading when published, but ING does not represent that it is accurate or complete. ING does not accept any liability for any direct, indirect or consequential loss arising from any use of this publication. Unless otherwise stated, any views, forecasts, or estimates are solely those of the author(s), as of the date of the publication and are subject to change without notice.
The distribution of this publication may be restricted by law or regulation in different jurisdictions and persons into whose possession this publication comes should inform themselves about, and observe, such restrictions.
Copyright and database rights protection exists in this report and it may not be reproduced, distributed or published by any person for any purpose without the prior express consent of ING. All rights are reserved.
ING Bank N.V. is authorised by the Dutch Central Bank and supervised by the European Central Bank (ECB), the Dutch Central Bank (DNB) and the Dutch Authority for the Financial Markets (AFM). ING Bank N.V. is incorporated in the Netherlands (Trade Register no. 33031431 Amsterdam).